MEG3 and esophageal squamous cell carcinoma: Treatment of EC cells with the DNA methyltransferase inhibitor 5-AZA-2’-deoxycytidine (5-Aza-dC) induced upregulation of MEG3, which suggested that promoter hypermethylation of MEG3 represents one of the mechanisms that decreases its expression in ESCC tissues.